壮骨活血汤结合带旋髂深血管蒂髂骨瓣移植治疗股骨头坏死临床研究

《壮骨活血汤结合带旋髂深血管蒂髂骨瓣移植治疗股骨头坏死临床研究》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。

1、提要目的:通过研究壮骨活血汤结合带旋髂深血管蒂髂骨瓣移植治疗ARCO分期Ⅱ-Ⅲ期股骨头无菌性坏死患者的Harris评分及X片改善情况，以验证该治疗方法的优势。方法:将40例（49髋）ARCO分期Ⅱ-Ⅲ期股骨头无菌性坏死患者随机分为两组。治疗组21例(28髋),采用旋髂深血管蒂髂骨瓣移植治疗，2周后服用壮骨活血汤3个疗程。对照组19例（21髋）,单纯采用旋髂深血管蒂髂骨瓣移植治疗。观察两组术后Harris评分及X片改善情况。结果:术后12个月后治疗组Harris评分及X片改善情况均优于对照组。结论:壮骨活血汤结合带旋髂深血管蒂髂骨瓣移植治疗AR

2、CO分期Ⅱ-Ⅲ期股骨头无菌性坏死的效果明显优于单纯旋髂深血管蒂髂骨瓣移植。关键词：壮骨活血汤；带血管蒂髂骨瓣移植；股骨头无菌性坏死ClinicalstudyonZhuangguhuoxuedecoctioncombinedwithvascularizediliacbonegraftingfortreatmentofOsteonecrosisoftheFemoralHeadSpeciality:OrthopaedicsofTCMAuthor:WangYuanxinTutor:ProfessorXingLifengAbstractObjectiv

3、e:TostudytheeffectofZhuangguhuoxuedecoctioncombinedwithvascularizediliacbonegraftingintreatmentforARCOstageⅡ-Ⅲosteonecrosisofthefemoralhead.Method:Fortypatientswith49hipsbeingatARCOstageⅡ-Ⅲwererandomlydividedintotwoguoups.Thetreatmentgroup(21patientswith28hips)weretreatedwi

4、thZhuangguhuoxuedecoctionforthreecourseoftreatmentaftertwoweeksofvascularizediliacbonegraftingsurgery.Thecontrolgroup(19patientswith21hips)wereoperatedwithvascularizediliacbonegrafting.ObservedthechangesofHarrishipscoreandX-rayfilmimage.Results:At12monthsaftertreatment,thep

5、romotionofHarrishipscoreandX-rayfilmimageintreatmentgroupweresignificantlybetterthanthatincontrolgroup.Conclusion:ZhuangguhuoxuedecoctioncombinedwithvascularizediliacbonegraftingismoreeffectivethanvascularizediliacbonegraftingintreatmentforARCOstageⅡ-Ⅲosteonecrosisofthefemo

6、ralhead.KeywordsZhuangguhuoxuedecoction;vascularizediliacbonegrafting;OsteonecrosisoftheFemoralHead目录引言...............................................................1临床研究...............................................................21临床资料..................................

7、...........................21.1一般资料...........................................................21.2诊断标准...........................................................21.3分类标准...........................................................21.4病例纳入标准....................................

8、...................31.5病例排除标准.....................................................